发明名称 Biomarkers for asthma
摘要 The present invention provides methods, kits, and compositions related to testing a sample for the level of a biomarker related to asthma, wherein the biomarker is selected from: taurine, maltose, maltotriose, adenosine 5′-monophosphate, phosphoethanolamine, glycerophosphorylcholine, arachidonate, heptanoate, pelargonate, and nicotinamide. In certain embodiments, the level of the biomarker is used to identify therapy effective for treating asthma. In other embodiments, the level of the biomarker is used to identify the presence, severity, or risk of exacerbation of asthma. In further embodiments, the level of the biomarker is used to monitor the response to on-going therapy (e.g., adjust the dosage of the asthma therapy).
申请公布号 US9410938(B2) 申请公布日期 2016.08.09
申请号 US201313893425 申请日期 2013.05.14
申请人 THE CLEVELAND CLINIC FOUNDATION 发明人 Comhair Suzy;Kalhan Satish;Hazen Stanley
分类号 A61B5/145;A61K31/40;A61K31/395;A61K47/18;G01N33/483;G01N33/49;G01N33/493 主分类号 A61B5/145
代理机构 Casimir Jones, S.C. 代理人 Casimir Jones, S.C. ;Bond Jason R.
主权项 1. A method of testing and treating a subject with asthma comprising: a) testing a plasma sample from a subject with asthma to determine the level of taurine, wherein said testing is performed by the use of liquid chromatography, gas chromatography, and/or mass spectrometry; and b) administering asthma therapy to said subject based on said level of taurine, wherein said asthma therapy is a non-steroidal therapeutic agent that is a leukotriene receptor antagonist (LTRA) if said level of taurine is at least 2-fold increased compared to a control level, and wherein said asthma therapy is a steroidal therapeutic agent if said level of taurine is not at least 2-fold increased compared to a control level.
地址 Cleveland OH US